Overview

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the efficacy of CJ-12420, once daily (QD), compared to esomeprazole in patients with erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8
Phase:
Phase 3
Details
Lead Sponsor:
CJ HealthCare Corporation
HK inno.N Corporation
Treatments:
Esomeprazole